David E Stec1, Kimberly P Gannon, Janis S Beaird, Heather A Drummond. 1. Department of Physiology and Biophysics, Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA. dstec@physiology.umsmed.edu
Abstract
AIM: We tested the hypothesis that 20-HETE production contributes to platelet derived growth factor (PDGF)-BB stimulated migration of VSMC in a cell culture model. METHODS: Studies were performed with A10 cells which are a rat vascular smooth muscle derived cell line. Migration was determined using a Boyden chamber chemotactic assay. RESULTS: Pre-treatment of cells with two doses of 20-HETE (100 and 500 nM) significantly increased PDGF-BB stimulated VSMC migration by 34-58% of control; whereas, prior incubation of cells with inhibitors of 20-HETE production, 17-ODYA (1-25 M) or HET0016 (100 nM), significantly decreased PDGF-BB stimulated migration by 40-90%. 20-HETE mediated increase in PDGF-BB migration was completely prevented by the 20-HETE antagonist, WIT-002. In order to determine what second messenger pathways are involved in the 20-HETE mediated stimulation of VSM migration, experiments were performed with specific inhibitors of tyrosine kinase (tyrphostin 25, 10 microM), mitogen-activated extracellular signal-regulated kinase (MEK, PD98059, 20 microM and U0126, 10 microM), protein kinase C (Myr-PKC, 50 microM), and phosphoinositide 3-kinases (PI3Ks) (wortmannin, 50 nM). Blockade of MEK and PI3K all abolished the increase in 20-HETE mediated migration. CONCLUSION: 20-HETE stimulates PDGF-mediated VSM migration acting through pathways that involve MEK and PI3K. Copyright 2007 S. Karger AG, Basel.
AIM: We tested the hypothesis that 20-HETE production contributes to platelet derived growth factor (PDGF)-BB stimulated migration of VSMC in a cell culture model. METHODS: Studies were performed with A10 cells which are a rat vascular smooth muscle derived cell line. Migration was determined using a Boyden chamber chemotactic assay. RESULTS: Pre-treatment of cells with two doses of 20-HETE (100 and 500 nM) significantly increased PDGF-BB stimulated VSMC migration by 34-58% of control; whereas, prior incubation of cells with inhibitors of 20-HETE production, 17-ODYA (1-25 M) or HET0016 (100 nM), significantly decreased PDGF-BB stimulated migration by 40-90%. 20-HETE mediated increase in PDGF-BB migration was completely prevented by the 20-HETE antagonist, WIT-002. In order to determine what second messenger pathways are involved in the 20-HETE mediated stimulation of VSM migration, experiments were performed with specific inhibitors of tyrosine kinase (tyrphostin 25, 10 microM), mitogen-activated extracellular signal-regulated kinase (MEK, PD98059, 20 microM and U0126, 10 microM), protein kinase C (Myr-PKC, 50 microM), and phosphoinositide 3-kinases (PI3Ks) (wortmannin, 50 nM). Blockade of MEK and PI3K all abolished the increase in 20-HETE mediated migration. CONCLUSION:20-HETE stimulates PDGF-mediated VSM migration acting through pathways that involve MEK and PI3K. Copyright 2007 S. Karger AG, Basel.
Authors: Jennifer Cheng; Victor Garcia; Yan Ding; Cheng-Chia Wu; Krutanjali Thakar; John R Falck; Errabelli Ramu; Michal Laniado Schwartzman Journal: Arterioscler Thromb Vasc Biol Date: 2012-06-21 Impact factor: 8.311
Authors: Ludwig D Orozco; Huiling Liu; Eddie Perkins; Daryl A Johnson; Betty B Chen; Fan Fan; Rodney C Baker; Richard J Roman Journal: J Pharmacol Exp Ther Date: 2013-05-08 Impact factor: 4.030
Authors: Fariborz A Yaghini; Chi Young Song; Eduard N Lavrentyev; Hafiz U B Ghafoor; Xiao R Fang; Anne M Estes; William B Campbell; Kafait U Malik Journal: Hypertension Date: 2010-05-03 Impact factor: 10.190
Authors: Li Chen; Gregory Joseph; Frank F Zhang; Huyen Nguyen; Houli Jiang; Katherine H Gotlinger; John R Falck; Jing Yang; Michal L Schwartzman; Austin M Guo Journal: Vascul Pharmacol Date: 2016-04-13 Impact factor: 5.773
Authors: Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang Journal: Cancer Chemother Pharmacol Date: 2010-12-01 Impact factor: 3.333
Authors: Jennifer Cheng; Cheng-Chia Wu; Katherine H Gotlinger; Frank Zhang; John R Falck; Dubasi Narsimhaswamy; Michal Laniado Schwartzman Journal: J Pharmacol Exp Ther Date: 2009-10-19 Impact factor: 4.030